RxDoctor Payments Data

Janice Semeyn, DO

Family Medicine · Clarion, PANPI 1669441127

Payments from drug & device makers

$7,223in general payments, 2019–2025

Across 515 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$667
  • Pfizer$454
  • Boehringer Ingelheim$414
  • Johnson & Johnson$389
  • AbbVie$387
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$7,187100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,223 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$151,237
Medicare patients
381
Services billed
2,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban542$216,976
JardianceEmpagliflozin275$174,077
OzempicSemaglutide152$161,993
TrulicityDulaglutide151$145,889
MounjaroTirzepatide99$101,998
MyrbetriqMirabegron242$83,500
JanuviaSitagliptin Phosphate181$69,768
XareltoRivaroxaban92$61,174
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$48,410
RybelsusSemaglutide41$47,868
Tresiba Flextouch U-100Insulin Degludec72$39,582
EntrestoSacubitril/Valsartan57$36,371
Tresiba Flextouch U-200Insulin Degludec50$34,012
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$21,395
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$18,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$258$247,887250 claims
PfizerEliquis$454$216,976542 claims
Novo NordiskOzempic, Rybelsus$1,424$209,861193 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$414$202,627318 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta$667$96,958205 claims
Astellas Pharma US IncMyrbetriq$180$83,500242 claims
MerckJanuvia, Lagevrio (Eua)$118$80,678196 claims
Johnson & JohnsonXarelto, Invokana$389$68,617104 claims
NovartisEntresto$195$36,37157 claims
AbbVieLinzess$387$16,41726 claims
AstraZenecaFarxiga$161$15,25540 claims
Sanofi-aventis U.S. LLCLantus$88$11,139124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Clarion

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →